BioCentury | Mar 30, 2015
Analyst Picks & Changes

Analyst picks & changes

...from $335.6M in 2016 and $432.1M from $609.6M in 2017. Genfit S.A. (Euronext:GNFT) Deutsche Bank Alethia...
BioCentury | Feb 23, 2015
Analyst Picks & Changes

Analyst picks & changes

...by Roche (SIX:ROG; OTCQX:RHHBY) and its Genentech Inc. unit. VBL Therapeutics Ltd. (NASDAQ:VBLT) Deutsche Bank Alethia...
BioCentury | Jan 26, 2015
Analyst Picks & Changes

Analyst picks & changes

...Company Bank Analyst Coverage Opinion Wk chg 1/23 cls Arrowhead Research Corp. (NASDAQ:ARWR) Deutsche Bank Alethia...
BioCentury | Sep 22, 2014
Analyst Picks & Changes

Analyst picks & changes

...docetaxel and is partnered with Astellas Pharma Inc. (Tokyo:4503). PTC Therapeutics Inc. (NASDAQ:PTCT) Deutsche Bank Alethia...
BioCentury | Jul 21, 2014
Analyst Picks & Changes

Analyst picks & changes

...changes Company Bank Analyst Coverage Opinion Wk chg 7/18 cls Genfit S.A. (Euronext:GNFT) Deutsche Bank Alethia...
BioCentury | Mar 13, 2014
Distillery Therapeutics

Indication: Musculoskeletal disease

...models of cancer-induced bone loss. SciBX 7(10); doi:10.1038/scibx.2014.288 Published online March 13, 2014 Patented by Alethia BioTherapeutics Inc....
...et al. J. Biol. Chem.; published online Jan. 20, 2014; doi:10.1074/jbc.M113.494542 Contact: Gilles B. Tremblay, Alethia BioTherapeutics Inc....
BioCentury | Jan 27, 2014
Analyst Picks & Changes

Analyst picks & changes

...diagnostic, medical imaging and surgical products for women's healthcare. Isis Pharmaceuticals Inc. (NASDAQ:ISIS) Deutsche Bank Alethia...
BioCentury | Oct 7, 2013
Analyst Picks & Changes

Analyst picks & changes

...Achillion Pharmaceuticals Inc. (NASDAQ:ACHN) Baird Brian Skorney Downgrade Neutral (from outperform) -62% $2.72 Deutsche Bank Alethia...
BioCentury | Jun 24, 2013
Analyst Picks & Changes

Analyst picks & changes

...Idenix Pharmaceuticals Inc. (NASDAQ:IDIX) Baird Brian Skorney Downgrade Underperform (from neutral) -31% $3.56 Deutsche Bank Alethia...
BioCentury | Jun 3, 2013
Company News

Alethia, International Biotech Center (IBC) Generium deal

...Alethia and IBC Generium partnered to co-develop Alethia's AB-16B5 , an IgG2 mAb against clusterin (CLU...
...AB-16B5 , an IgG2 mAb against clusterin (CLU; APOJ ) in preclinical testing for cancer. Alethia...
...in June 2014. The partners said they will determine further development responsibilities during the trial. Alethia...
Items per page:
1 - 10 of 23
BioCentury | Mar 30, 2015
Analyst Picks & Changes

Analyst picks & changes

...from $335.6M in 2016 and $432.1M from $609.6M in 2017. Genfit S.A. (Euronext:GNFT) Deutsche Bank Alethia...
BioCentury | Feb 23, 2015
Analyst Picks & Changes

Analyst picks & changes

...by Roche (SIX:ROG; OTCQX:RHHBY) and its Genentech Inc. unit. VBL Therapeutics Ltd. (NASDAQ:VBLT) Deutsche Bank Alethia...
BioCentury | Jan 26, 2015
Analyst Picks & Changes

Analyst picks & changes

...Company Bank Analyst Coverage Opinion Wk chg 1/23 cls Arrowhead Research Corp. (NASDAQ:ARWR) Deutsche Bank Alethia...
BioCentury | Sep 22, 2014
Analyst Picks & Changes

Analyst picks & changes

...docetaxel and is partnered with Astellas Pharma Inc. (Tokyo:4503). PTC Therapeutics Inc. (NASDAQ:PTCT) Deutsche Bank Alethia...
BioCentury | Jul 21, 2014
Analyst Picks & Changes

Analyst picks & changes

...changes Company Bank Analyst Coverage Opinion Wk chg 7/18 cls Genfit S.A. (Euronext:GNFT) Deutsche Bank Alethia...
BioCentury | Mar 13, 2014
Distillery Therapeutics

Indication: Musculoskeletal disease

...models of cancer-induced bone loss. SciBX 7(10); doi:10.1038/scibx.2014.288 Published online March 13, 2014 Patented by Alethia BioTherapeutics Inc....
...et al. J. Biol. Chem.; published online Jan. 20, 2014; doi:10.1074/jbc.M113.494542 Contact: Gilles B. Tremblay, Alethia BioTherapeutics Inc....
BioCentury | Jan 27, 2014
Analyst Picks & Changes

Analyst picks & changes

...diagnostic, medical imaging and surgical products for women's healthcare. Isis Pharmaceuticals Inc. (NASDAQ:ISIS) Deutsche Bank Alethia...
BioCentury | Oct 7, 2013
Analyst Picks & Changes

Analyst picks & changes

...Achillion Pharmaceuticals Inc. (NASDAQ:ACHN) Baird Brian Skorney Downgrade Neutral (from outperform) -62% $2.72 Deutsche Bank Alethia...
BioCentury | Jun 24, 2013
Analyst Picks & Changes

Analyst picks & changes

...Idenix Pharmaceuticals Inc. (NASDAQ:IDIX) Baird Brian Skorney Downgrade Underperform (from neutral) -31% $3.56 Deutsche Bank Alethia...
BioCentury | Jun 3, 2013
Company News

Alethia, International Biotech Center (IBC) Generium deal

...Alethia and IBC Generium partnered to co-develop Alethia's AB-16B5 , an IgG2 mAb against clusterin (CLU...
...AB-16B5 , an IgG2 mAb against clusterin (CLU; APOJ ) in preclinical testing for cancer. Alethia...
...in June 2014. The partners said they will determine further development responsibilities during the trial. Alethia...
Items per page:
1 - 10 of 23